Accounting giant Ernst & Young will pay $4 million to settle civil charges that it violated auditor independence rules, U.S. regulators said.» Read More
Amgen Inc. rose $2.08 or 1.7 percent, to $121.11. Biogen Idec rose $1.17 or. 4 percent, to $303.67. Celgene Corp. rose $1.35 or 1.6 percent, to $86.66.
Amgen Inc. rose $1.68 or 1.4 percent, to $120.71. Biogen Idec rose $2.64 or. 9 percent, to $305.14. Celgene Corp. rose $1.30 or 1.5 percent, to $86.61.
Amgen Inc. rose $1.30 or 1.1 percent, to $120.33. Biogen Idec rose $5.25 or 1.7 percent, to $307.75. Celgene Corp. rose $1.69 or 2.0 percent, to $87.00.
Amgen Inc. rose$. 05 or percent, to $116.91. Biogen Idec fell $6.64 or 2.1 percent, to $305.36. Celgene Corp. fell$. 70 or. 8 percent, to $86.08.
Amgen Inc. rose$. 29 or. 3 percent, to $117.16. Biogen Idec fell $4.28 or 1.4 percent, to $307.72. Celgene Corp. rose$. 21 or. 2 percent, to $86.99.
In 2012, Ernst& Young voluntarily decided to cease performing lobbying work for SEC registrant audit clients. " "Auditor independence is critical to the integrity of the financial reporting process," said Scott Friestad, an associate director in the SEC's enforcement division.
Amgen Inc. fell$. 54 or. 5 percent, to $119.23. Biogen Idec fell $2.91 or. 9 percent, to $319.31. Celgene Corp. fell $1.01 or 1.1 percent, to $88.18.
Amgen Inc. fell$. 27 or. 2 percent, to $119.50. Biogen Idec fell$. 76 or. 2 percent, to $321.46. Celgene Corp. fell$. 93 or 1.0 percent, to $88.26.
Amgen Inc. rose$. 37 or. 3 percent, to $119.32. Biogen Idec fell $1.42 or. 4 percent, to $317.70. Celgene Corp. fell$. 05 or. 1 percent, to $87.78.
July 2- Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.
*Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.
LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.
*Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.
LONDON, June 16- London- listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the healthcare sector, sources familiar with the matter told Reuters.
CHICAGO, June 6- A new way of evaluating tumors may soon help cancer patients identify the underlying genetic link to their disease- and the best possible treatment- all in a single test. "We really are moving away from this one drug, one biomarker, one companion diagnostic," said Dr Richard Pazdur, the U.S. Food and Drug Administration's oncology chief.
Some of the names on the move ahead of the open.
FRANKFURT, May 23- U.S. health regulators on Friday approved Qiagen NV's gene-testing kit to identify those colorectal cancer patients most likely to benefit from Amgen Inc's drug, Vectibix, Qiagen said.
May 23- For two months last summer, Stanford Law School professor Joseph Grundfest locked himself away in his home office in California's Portola Valley.
Stocks may be rallying Wednesday, but there are still plenty of industries that have lost substantial ground.
*Sanofi has restructured R&D, has strong pipeline-Zerhouni. PARIS, May 15- France's Sanofi has strengthened its drug pipeline and has enough future blockbusters lined up for it to steer clear of the M&A frenzy "overheating" the industry, the drugmaker's R&D chief told Reuters.